サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1777562

皮膚がん診断の世界市場

Skin Cancer Diagnostics

出版日
ページ情報
英文 370 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.98円
皮膚がん診断の世界市場
出版日: 2025年07月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 370 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

皮膚がん診断の世界市場は2030年までに117億米ドルに到達

2024年に94億米ドルと推定される皮膚がん診断の世界市場は、2024～2030年の分析期間にCAGR 3.8％で成長し、2030年には117億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるメラノーマは、CAGR 3.0％を記録し、分析期間終了時には70億米ドルに達すると予測されます。非黒色腫セグメントの成長率は、分析期間中CAGR 5.0％と推定されます。

米国市場は25億米ドルと推定、中国はCAGR 6.8％で成長予測

米国の皮膚がん診断市場は2024年に25億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR6.8％を引きずる形で、2030年までに市場規模が23億米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.6%と2.9%と予測されています。欧州では、ドイツがCAGR 2.2%で成長すると予測されています。

世界の皮膚がん診断市場- 主要動向と促進要因のまとめ

なぜ皮膚がん診断は世界のヘルスケアにおける優先事項になりつつあるのか？皮膚悪性腫瘍の発生率の増加

皮膚がん、特にメラノーマや基底細胞がん、扁平上皮がんなどの非メラノーマの有病率の増加により、早期発見が皮膚科および腫瘍学の重要な優先事項となっています。紫外線曝露の増加、気候変動、遺伝的素因、生活習慣などの要因が、世界の皮膚悪性腫瘍の発生率上昇に寄与しています。公衆衛生上の取り組みとして早期診断の重要性が強調される中、皮膚がん診断の進歩は生存率の向上に重要な役割を果たしています。視診や生検といった伝統的な診断法は依然としてゴールドスタンダードであるが、非侵襲的な画像診断技術の導入は診断の状況を一変させました。さらに、啓発キャンペーンや定期的なスキンチェックの増加により、より多くの人々が早期検診を受けるようになり、より高い発見率につながっています。ヘルスケアシステムが予防医療に引き続き注力する中、正確で効率的な皮膚がん診断ツールの需要は大幅に増加すると予想されます。

技術革新はどのように皮膚がん診断を強化しているのか？AI、画像診断、分子検査の役割を探る

皮膚がん診断の分野は、最先端の技術によって検出精度が向上し、不要な生検の必要性が減少するなど、大きな進歩を遂げています。ダーモスコピー、共焦点レーザー顕微鏡、反射型共焦点顕微鏡は、皮膚科医に高解像度の画像診断能力を提供し、疑わしい病変をリアルタイムで評価できるようになりました。人工知能（AI）と機械学習はこの分野にさらなる革命をもたらし、AIを搭載したアルゴリズムは皮膚画像を分析し、驚くべき精度でがんパターンを特定できるようになりました。さらに、遺伝子診断や分子診断が皮膚がん検出の強力なツールとして登場し、メラノーマのリスクに関連する遺伝子変異の同定を可能にしています。リキッドバイオプシー技術もまた、血液サンプル中の循環腫瘍DNA（ctDNA）を検出する可能性が検討されており、従来の生検法に代わる低侵襲な方法を提供しています。これらの技術革新が進化し続けるにつれ、皮膚がん診断はより利用しやすく、効率的で、信頼できるものになってきています。

先進的な皮膚がん診断ツールの普及を妨げている課題とは？コスト、アクセシビリティ、規制の問題への対応

皮膚がん診断の技術的進歩にもかかわらず、コストの障壁、アクセシビリティの問題、規制の複雑さなど、いくつかの課題が残っています。高度な画像診断システムやAIを活用した診断プラットフォームは多額の投資を必要とするため、皮膚がんの発見が最も必要とされる低所得層や遠隔地では利用しにくくなっています。さらに、地域によってヘルスケア・インフラにばらつきがあるため、診断結果を正確に解釈できる熟練した皮膚科医や腫瘍内科医の確保にも影響があります。AIベースの診断ツールの信頼性と標準化を確保することは依然として重要なハードルであるため、皮膚科へのAIの統合は規制上の懸念も引き起こします。さらに、早期スクリーニングや非侵襲的診断の利点に関する患者の意識は、世界の多くの地域ではまだ限定的であり、診断の遅れや予後の悪化につながっています。このような課題を克服するには、コスト削減、規制の調整、遠隔医療ソリューションの広範な導入など、世界の皮膚がん発見率を向上させるための戦略的取り組みが必要です。

皮膚がん診断市場の成長を促すものは何か？主な拡大要因と業界動向の特定

皮膚がん診断市場の成長は、皮膚がんの罹患率の増加、診断技術の進歩、AIを活用したスクリーニングソリューションの採用増加など、いくつかの要因によってもたらされます。メラノーマやメラノーマ以外の皮膚がんの負担が増加していることから、政府やヘルスケア機関は早期発見プログラムに投資しており、診断ツールの需要をさらに押し上げています。遠隔皮膚科学とAIベースの画像解析の台頭により、皮膚がん検診へのアクセスが拡大し、遠隔評価と迅速な診断が可能になりました。さらに、紫外線曝露の危険性と定期的な皮膚チェックの重要性に関する消費者の意識の高まりが、積極的な健康監視を促しています。遺伝子検査や分子検査における革新もまた、精密診断の新たな道を開き、より的を絞った効果的な治療戦略を可能にしています。診断精度、手頃な価格、アクセスの継続的な改善により、皮膚がん診断市場は大幅な拡大が見込まれ、皮膚腫瘍学の将来を形成しています。

セグメント

がんの種類（黒色腫、非黒色腫）;検査の種類（皮膚鏡検査、皮膚生検、リンパ節生検、画像検査、その他）;エンドユーザー（病院＆クリニック、研究所、その他）

調査対象企業の例

  • Abbott Laboratories
  • Amgen Inc.
  • AMLo Biosciences
  • Bristol-Myers Squibb Company
  • Caliber Imaging & Diagnostics, Inc.
  • Canfield Scientific, Inc.
  • Castle Biosciences, Inc.
  • Daiichi Sankyo Company, Limited
  • DermaSensor, Inc.
  • DermLite
  • DermTech
  • F. Hoffmann-La Roche Ltd
  • FotoFinder Systems GmbH
  • Genomic Health（Exact Sciences）
  • Laboratory Corporation of America
  • Merck & Co., Inc.
  • Michelson Diagnostics
  • Myriad Genetics
  • Neko Health
  • NeoGenomics Laboratories
  • Novartis AG
  • Pfizer Inc.
  • Proscia
  • QIAGEN
  • Sanofi
  • Scailyte AG
  • Sirnaomics, Inc.
  • SkinVision
  • Sun Pharmaceutical Industries Ltd
  • Veriskin Inc

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32952

Global Skin Cancer Diagnostics Market to Reach US$11.7 Billion by 2030

The global market for Skin Cancer Diagnostics estimated at US$9.4 Billion in the year 2024, is expected to reach US$11.7 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Melanoma, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$7.0 Billion by the end of the analysis period. Growth in the Non-Melanoma segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.5 Billion While China is Forecast to Grow at 6.8% CAGR

The Skin Cancer Diagnostics market in the U.S. is estimated at US$2.5 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Skin Cancer Diagnostics Market - Key Trends & Drivers Summarized

Why Is Skin Cancer Diagnostics Becoming a Global Healthcare Priority? Examining the Rising Incidence of Skin Malignancies

The growing prevalence of skin cancer, particularly melanoma and non-melanoma variants such as basal cell carcinoma and squamous cell carcinoma, has made early detection a critical priority in dermatology and oncology. Factors such as increased UV exposure, climate change, genetic predisposition, and lifestyle habits have contributed to the rising incidence of skin malignancies worldwide. With public health initiatives emphasizing the importance of early diagnosis, advancements in skin cancer diagnostics have played a crucial role in improving survival rates. Traditional diagnostic methods such as visual inspection and biopsy remain the gold standard, but the introduction of non-invasive imaging technologies has transformed the diagnostic landscape. Additionally, increasing awareness campaigns and routine skin checks have encouraged more individuals to seek early screening, leading to higher detection rates. As healthcare systems continue to focus on preventive care, the demand for accurate and efficient skin cancer diagnostic tools is expected to rise significantly.

How Are Technological Innovations Enhancing Skin Cancer Diagnostics? Exploring the Role of AI, Imaging, and Molecular Testing

The field of skin cancer diagnostics has witnessed significant advancements, with cutting-edge technologies improving detection accuracy and reducing the need for unnecessary biopsies. Dermoscopy, confocal laser scanning microscopy, and reflectance confocal microscopy have provided dermatologists with high-resolution imaging capabilities, allowing for real-time evaluation of suspicious lesions. Artificial intelligence (AI) and machine learning have further revolutionized the field, with AI-powered algorithms capable of analyzing skin images and identifying cancerous patterns with remarkable precision. Additionally, genetic and molecular diagnostics have emerged as powerful tools in skin cancer detection, enabling the identification of genetic mutations associated with melanoma risk. Liquid biopsy techniques are also being explored for their potential to detect circulating tumor DNA (ctDNA) in blood samples, providing a minimally invasive alternative to traditional biopsy methods. As these innovations continue to evolve, skin cancer diagnostics are becoming more accessible, efficient, and reliable.

What Challenges Are Hindering the Adoption of Advanced Skin Cancer Diagnostic Tools? Addressing Cost, Accessibility, and Regulatory Issues

Despite the technological progress in skin cancer diagnostics, several challenges remain, including cost barriers, accessibility issues, and regulatory complexities. Advanced imaging systems and AI-driven diagnostic platforms require significant investment, making them less accessible in low-income and remote areas where skin cancer detection is needed most. Additionally, variations in healthcare infrastructure across regions impact the availability of skilled dermatologists and oncologists who can interpret diagnostic results accurately. The integration of AI into dermatology also raises regulatory concerns, as ensuring the reliability and standardization of AI-based diagnostic tools remains a key hurdle. Furthermore, patient awareness about early screening and the benefits of non-invasive diagnostics is still limited in many parts of the world, leading to delayed diagnoses and poorer outcomes. Overcoming these challenges requires strategic efforts in cost reduction, regulatory alignment, and broader implementation of telemedicine solutions to improve global skin cancer detection rates.

What’s Driving the Growth of the Skin Cancer Diagnostics Market? Identifying Key Expansion Factors and Industry Trends

The growth in the skin cancer diagnostics market is driven by several factors, including increasing incidence rates of skin cancer, advancements in diagnostic technology, and the rising adoption of AI-powered screening solutions. The growing burden of melanoma and non-melanoma skin cancers has led governments and healthcare organizations to invest in early detection programs, further boosting demand for diagnostic tools. The rise of teledermatology and AI-based image analysis has expanded access to skin cancer screening, allowing for remote assessments and faster diagnosis. Additionally, increasing consumer awareness about the dangers of UV exposure and the importance of routine skin checks has encouraged proactive health monitoring. Innovations in genetic and molecular testing have also opened new avenues for precision diagnostics, enabling more targeted and effective treatment strategies. With continuous improvements in diagnostic accuracy, affordability, and accessibility, the skin cancer diagnostics market is expected to experience significant expansion, shaping the future of dermatological oncology.

SCOPE OF STUDY:

The report analyzes the Skin Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Cancer Type (Melanoma, Non-Melanoma); Test Type (Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests, Others); End-Use (Hospitals & Clinics, Laboratories, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott Laboratories
  • Amgen Inc.
  • AMLo Biosciences
  • Bristol-Myers Squibb Company
  • Caliber Imaging & Diagnostics, Inc.
  • Canfield Scientific, Inc.
  • Castle Biosciences, Inc.
  • Daiichi Sankyo Company, Limited
  • DermaSensor, Inc.
  • DermLite
  • DermTech
  • F. Hoffmann-La Roche Ltd
  • FotoFinder Systems GmbH
  • Genomic Health (Exact Sciences)
  • Laboratory Corporation of America
  • Merck & Co., Inc.
  • Michelson Diagnostics
  • Myriad Genetics
  • Neko Health
  • NeoGenomics Laboratories
  • Novartis AG
  • Pfizer Inc.
  • Proscia
  • QIAGEN
  • Sanofi
  • Scailyte AG
  • Sirnaomics, Inc.
  • SkinVision
  • Sun Pharmaceutical Industries Ltd
  • Veriskin Inc

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Skin Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Melanoma and Non-Melanoma Skin Cancers Throws the Spotlight on Early Diagnostic Tools
    • Expansion of UV Exposure and Aging Population Trends Drives Skin Cancer Screening Volumes Worldwide
    • OEM Innovation in Dermatoscopic Imaging and Optical Coherence Tomography Enhances Diagnostic Accuracy
    • Growth in AI-Powered Diagnostic Platforms Supports Clinical Decision Making and Teledermatology Services
    • OEM Development of Smartphone-Integrated and Handheld Devices Enables Point-of-Care Skin Lesion Assessment
    • Rising Government Funding for Cancer Prevention Programs Accelerates Public Screening and Risk Awareness
    • OEM Emphasis on Machine Learning Algorithms for Lesion Classification Reduces Diagnostic Variability
    • Expansion of Molecular and Genetic Testing for Skin Cancer Supports Personalized Therapy Selection
    • OEM Integration of Image Archiving and Patient Monitoring Systems Enhances Long-Term Surveillance
    • Surge in Biopsy Avoidance and Non-Invasive Testing Preferences Propels Demand for Optical Diagnostics
    • OEM Collaboration With Dermatology Networks and Primary Care Providers Expands Access to Early Detection Tools
    • Growth in Pigmented Lesion Clinics and Mobile Diagnostic Units Supports Outreach in Underserved Regions
    • OEM Strategies for CE and FDA Approvals Enhance Global Market Penetration and Reimbursement Readiness
    • Increasing Awareness of Actinic Keratosis and Precancerous Conditions Supports Preventive Screening Growth
    • OEM Investment in Predictive Analytics and Decision Support Tools Enhances Workflow Integration
    • Rising Demand for Full-Body Scanning Systems in High-Risk Individuals Spurs Technology Adoption
    • OEM Partnerships With Insurers and Public Health Agencies Facilitate Coverage of Digital Skin Exams
    • Expansion of Skin Cancer Awareness Campaigns Reinforces Proactive Dermatology Visits and Device Demand
    • OEM Emphasis on Lightweight, Portable Diagnostic Solutions Supports Use in Home Visits and Rural Clinics
    • Focus on Accuracy, Speed, and Cost-Effectiveness Strengthens Business Case for Diagnostic Innovation in Dermatology
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Skin Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Skin Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Skin Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Dermatoscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Dermatoscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Dermatoscopy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Skin Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Skin Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Skin Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Lymph Node Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Lymph Node Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Lymph Node Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Imaging Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Imaging Tests by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • JAPAN
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • CHINA
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • EUROPE
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Skin Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Skin Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • FRANCE
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • GERMANY
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Skin Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Skin Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • INDIA
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Skin Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Skin Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Skin Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Skin Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030
  • AFRICA
    • Skin Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Skin Cancer Diagnostics by Cancer Type - Melanoma and Non-Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Skin Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Melanoma and Non-Melanoma for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Skin Cancer Diagnostics by End-Use - Other End-Uses, Hospitals & Clinics and Laboratories Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Skin Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals & Clinics and Laboratories for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Skin Cancer Diagnostics by Test Type - Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Skin Cancer Diagnostics by Test Type - Percentage Breakdown of Value Sales for Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests and Other Test Types for the Years 2015, 2025 & 2030

IV. COMPETITION